Literature DB >> 17107905

HFE gene mutations in patients with acute leukemia.

Assunta Viola1, Leonilde Pagano, Daniela Laudati, Rossella D'Elia, Maria Rosaria D'Amico, Massimiliano Ammirabile, Salvatore Palmieri, Luciano Prossomariti, Felicetto Ferrara.   

Abstract

An increased incidence of HFE gene mutations has been described in hematologic malignancies. In the present study, we investigated the allelic frequency of HFE gene mutations in 154 adult patients with acute leukemia (AL) [107 acute myeloid leukemia (AML), 20 acute promyelocytic leukemia (APL) and 27 acute lymphoblastic leukemia (ALL)]. The allelic frequency of the H63D mutation was 29% in AL patients and 25% in the healthy controls [P = 0.41; odds ratio (OR) = 1.20; 95% confidence interval (CI) = 0.77 - 1.93]. No difference was found between controls and AML or APL patients, whereas the H63D mutation was significantly more frequent in ALL than controls (44% vs. 25%, P = 0.04; OR = 2.37; 95% CI = 1.05 - 5.36). The overall comparison of the mutation among the three subtypes of AL demonstrated a higher allelic frequency in ALL (P = 0.02). In conclusion, our data demonstrate a correlation between the presence of the H63D mutation and the occurrence of ALL in adult patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17107905     DOI: 10.1080/10428190600821898

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  7 in total

1.  HFE polymorphisms affect survival of brain tumor patients.

Authors:  Sang Y Lee; Becky Slagle-Webb; Jonas M Sheehan; Junjia Zhu; Joshua E Muscat; Michael Glantz; James R Connor
Journal:  J Neurooncol       Date:  2014-12-10       Impact factor: 4.130

2.  An automated bayesian framework for integrative gene expression analysis and predictive medicine.

Authors:  Neena Parikh; Amin Zollanvari; Gil Alterovitz
Journal:  AMIA Jt Summits Transl Sci Proc       Date:  2012-03-19

3.  Evaluation of Different Normalization and Analysis Procedures for Illumina Gene Expression Microarray Data Involving Small Changes.

Authors:  Daniel M Johnstone; Carlos Riveros; Moones Heidari; Ross M Graham; Debbie Trinder; Regina Berretta; John K Olynyk; Rodney J Scott; Pablo Moscato; Elizabeth A Milward
Journal:  Microarrays (Basel)       Date:  2013-05-21

4.  Impact of HFE variants and sex in lung cancer.

Authors:  Sang Y Lee; Vonn Walter; Junjia Zhu; Anna C Salzberg; Dajiang J Liu; James R Connor
Journal:  PLoS One       Date:  2019-12-19       Impact factor: 3.240

Review 5.  The Clinical Significance of Iron Overload and Iron Metabolism in Myelodysplastic Syndrome and Acute Myeloid Leukemia.

Authors:  Sarah Weber; Anastasia Parmon; Nina Kurrle; Frank Schnütgen; Hubert Serve
Journal:  Front Immunol       Date:  2021-02-19       Impact factor: 7.561

6.  Hemochromatosis (HFE) gene mutations and risk of gastric cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC) study.

Authors:  Antonio Agudo; Catalina Bonet; Núria Sala; Xavier Muñoz; Núria Aranda; Ana Fonseca-Nunes; Françoise Clavel-Chapelon; Marie Christine Boutron-Ruault; Paolo Vineis; Salvatore Panico; Domenico Palli; Rosario Tumino; Sara Grioni; J Ramón Quirós; Esther Molina; Carmen Navarro; Aurelio Barricarte; Saioa Chamosa; Naomi E Allen; Kay-Tee Khaw; H Bas Bueno-de-Mesquita; Peter D Siersema; Mattijs E Numans; Antonia Trichopoulou; Pagona Lagiou; Dimitrios Trichopoulos; Rudof Kaaks; Federico Canzian; Heiner Boeing; Karina Meidtner; Mattias Johansson; Malin Sund; Jonas Manjer; Kim Overvad; Anne Tjonneland; Eiliv Lund; Elisabete Weiderpass; Mazda Jenab; Veronika Fedirko; G Johan A Offerhaus; Elio Riboli; Carlos A González; Paula Jakszyn
Journal:  Carcinogenesis       Date:  2013-02-06       Impact factor: 4.944

Review 7.  EnvIRONmental Aspects in Myelodysplastic Syndrome.

Authors:  Verena Petzer; Igor Theurl; Günter Weiss; Dominik Wolf
Journal:  Int J Mol Sci       Date:  2021-05-14       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.